Robust and high-yielding platform process for plasmid DNA production
How Syngene scientists developed a platform process for plasmid DNA production with high titers of > 1 g/L upstream with >25% recovery downstream.
Process development and scale-up of highly challenging biomolecules
Three case studies on downstream platform process development for antibody fragments, three broadly neutralizing antibodies (bNAbs) against HIV, and a new class of regenerative implant used for treating a degenerative disease.
Mycoplasma Contamination Detection in Biopharmaceuticals
Presenting impact of Mycoplasma contamination, available testing methods, and why Syngene prefers NAT-based Mycoplasma detection method over other methods.